Virginia Economic Review

As the world continues to struggle with drug supply chains and critical shortages, clusters of activity have emerged to move the needle of medication affordability and accessibility.

John Newby is the CEO of Virginia Bio, the nonprofit statewide trade association that serves and promotes the life sciences industry in Virginia.

Recent major biopharmaceutical manufacturing announcements are positioning Virginia for a broader reshoring effort in the pharma industry. COVID-era supply chain disruptions and resulting shortages exposed the risks of over-reliance on overseas production for essential medicines.

A pharmaceutical manufacturing innovation that came out of a Virginia university is changing the way medicines are made. The Commonwealth’s universities and the rest of its biopharma research community are making sure Virginia is ready to make the medicines of the future.

Would more men try to prevent unintended pregnancies if their choices for contraception went beyond a condom or vasectomy?

The I95-I85 Intersection is anchored by the Tri-Cities of Petersburg (home to Civica Rx’s facility that produces a wide variety of affordable essential medicines), Hopewell, and Colonial Heights.

A lot changed in Virginia’s life sciences industry in the space of about a month last fall. Between Sept. 16 and Oct. 20, biopharmaceutical manufacturing giants Eli Lilly and Company, AstraZeneca, and Merck & Co.

New or expanding companies want to know that they will be able to hire workers with the skills they need. While outside training providers offer established but generic faculty, facilities, and programs, in-house solutions allow for customization but require significant investment.

Like his fellow Type 1 diabetics, Alec Smith took insulin every day to regulate his blood sugar.